Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Haemonetics CorporationNYSE: HAE

Net Margin · Q1 FY2027 · quarter ended Jun 2026

Net margin narrows to 9.7%

Net margin was 9.7% in Q1 FY2027, down 0.9 pp from a year earlier. On a trailing-twelve-month basis it was 7.1%, down 5.0 pp year over year. Over 3 fiscal years it narrowed by 2.6 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2026 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 10 analysts of 17.5% for the fiscal year ending Mar 2027, up from 7.3% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
9.7%+15.5 pp QoQ
Last fiscal yearMar 2026
7.3%-5.0 pp YoY
LTMJun 2026
7.1%-5.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.9 pp+5.6 pp+6.4 pp
1 year-5.0 pp+10.2 pp+15.3 pp
3 years-2.6 pp+11.9 pp+14.5 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2026
7.3%
Year-over-year change
-5.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 net margin of 7.1% is the 4th highest of the 10 companies compared; the peer median is 0.8%.
  • Its year-over-year change of -5.0 pp is the 8th highest of 10, against a peer median of +2.0 pp.
  • Over three fiscal years its change of -2.6 pp compares with a peer median of +4.3 pp.
HAE Competitors Peer median
Net Margin for HAE and competitors
Company Period LTM level YoY 3-year change
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202637.1% +0.2 pp-2.4 pp
LMATLeMaitre Vascular, Inc.LTM Mar 202624.3% +4.4 pp+10.4 pp
CONConcentra Group Holdings Parent, Inc.LTM Sep 20269.3% +1.9 pp-2.0 pp
HAEHaemonetics CorporationLTM Jun 20267.1% -5.0 pp-2.6 pp
ITGRInteger Holdings CorporationLTM Jul 20267.0% +2.4 pp+0.6 pp
WRBYWarby Parker Inc.LTM Jun 20260.8% +2.0 pp+18.6 pp
BHCBausch Health Companies Inc.LTM Jun 2026-10.1% -11.1 pp+4.3 pp
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026-17.1% +7.4 pp+8.0 pp
QDELQuidelOrtho CorporationLTM Mar 2026-45.6% -32.6 pp-58.3 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+417.3 pp
Peer median (excluding HAE) 0.8%+2.0 pp+4.3 pp

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue993.2M1.17B1.31B1.36B1.33B
Cost of Revenue462.43M545.79M597.14M582.28M590.44M
Gross Profit530.77M622.87M711.92M778.55M743.59M
Gross Margin53.4%53.3%54.4%57.2%55.7%
Research & Development55.2M58.63M63.04M69.42M59.77M
Selling, General & Admin332.2M373.95M420.82M422.05M442.42M
Operating Expenses450.02M466.84M547.03M556.73M502.19M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
EBITDA202.92M260.51M304.05M362.69M268.45M
EBITDA Margin20.4%22.3%23.2%26.7%20.1%
Operating Income80.75M156.03M164.88M221.82M241.4M
Operating Margin8.1%13.4%12.6%16.3%18.1%
Interest Income00000
Interest Expense17.12M14.63M13.02M9.75M28.7M
Other Income / Expenses(17.12M)(14.63M)(13.02M)(9.75M)(113.37M)
Income Before Tax63.63M141.4M151.87M212.07M128.03M
Pre-Tax Margin6.4%12.1%11.6%15.6%9.6%
Income Tax Expense20.25M26M34.31M44.39M30.72M
Net Income43.38M115.4M117.56M167.68M97.31M
Net Margin4.4%9.9%9.0%12.3%7.3%
EPS (Basic)0.852.272.323.312.05
EPS (Diluted)0.842.242.293.312.05
Weighted Avg Shares51.05M50.78M50.71M50.33M47.18M
Weighted Avg Shares (Diluted)51.35M51.42M51.4M50.73M47.35M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.